Friday, April 05, 2019 2:24:46 PM
From Motley Fool:
Zynteglo: Positive opinion
Until recently, this experimental therapy has been known as LentiGlobin because it uses a lentivirus to insert functional hemoglobin genes into stem cells that produce new blood cells. This treatment could be used for patients with transfusion-dependent thalassemia (TDT) and sickle cell disease (SCD). Both of these conditions are caused by dysfunctional genes for hemoglobin, the protein in red blood cells that carries oxygen to tissues that need it.
Recently, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended conditional approval of Zynteglo for TDT patients who can't find a matched stem cell donor. If the European Commission follows CHMP's opinion, as it usually does, this will be the first available treatment for TDT besides frequent blood transfusions, which are painful, inconvenient, and expensive.
If approved in the EU in the first half of 2019, and the U.S. in 2021, annual Zynteglo sales could reach $1.12 billion in 2023. Partly because it looked extremely effective in the Northstar-2 study, where 10 out of 11 treated patients had stopped receiving blood transfusions and had hemoglobin levels up near the normal range after three months.
Around 60,000 people inherit some form of beta-thalassemia, and a large portion of this population could be eligible for treatment with Zynteglo. That's probably enough to drive blockbuster sales on its own, and approval for SCD down the line could push this gene therapy even further. In the U.S. alone, there are about 100,000 people living with SCD, and perhaps a million worldwide that could use a treatment option. Misformed hemoglobin causes red blood cells to flatten out in a way that isn't helpful. Sickle-shaped blood cells get stuck in blood vessels, effectively strangling the organs they service and causing a great deal of pain along the way.
Recent CYRX News
- Cryoport to Report First Quarter 2024 Financial Results on May 7, 2024 • PR Newswire (US) • 04/30/2024 12:30:00 PM
- Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 03/12/2024 08:05:00 PM
- Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 • PR Newswire (US) • 02/27/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:42:22 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 05:22:50 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:23:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/21/2023 09:30:37 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/20/2023 05:15:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:19:00 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/15/2023 10:09:12 PM
- Form POSASR - Post-effective Amendment to an automatic shelf registration statement • Edgar (US Regulatory) • 12/15/2023 10:05:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 11:02:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/11/2023 10:09:00 PM
- Cryoport and NIPPON EXPRESS HOLDINGS Form Global Strategic Partnership for Temperature-Controlled Supply Chain Services • PR Newswire (US) • 11/27/2023 01:30:00 PM
- Cryoport's CRYOPDP Expands U.S. Footprint with Acquisition of Bluebird Express • PR Newswire (US) • 11/16/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:30:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 07:18:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:31:41 PM
- Cryoport Reports Third Quarter 2023 Financial Results • PR Newswire (US) • 11/08/2023 09:05:00 PM
- Cryoport Continues its Expansion in the European Market with Tec4med Lifescience GmbH Acquisition • PR Newswire (US) • 11/02/2023 12:30:00 PM
- Cryoport to Report Third Quarter 2023 Financial Results on November 8, 2023 • PR Newswire (US) • 10/25/2023 12:30:00 PM
- Cryoport Inks New Multi-Year Supply Chain Solutions Agreement with Monash IVF • PR Newswire (US) • 10/12/2023 12:30:00 PM
- Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies • PR Newswire (US) • 10/10/2023 12:30:00 PM
- Be The Match BioTherapies® and Cryoport Partner to Accelerate the Development of Cell and Gene Therapies • PR Newswire (US) • 10/09/2023 08:05:00 PM
- Cryoport Receives 2023 IMAPAC Asia Pacific Cell & Gene Therapy Excellence Award • PR Newswire (US) • 09/14/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM